Kanghong Pharmaceutical wins approval for new adult schizophrenia drug

Chengdu Kanghong Pharmaceutical Group Co., Ltd. announced the receipt of Drug Registration Certificates from the National Medical Products Administration for Brexpiprazole Tablets. The approved drug, available in 1mg and 2mg dosages, is indicated for the treatment of adult schizophrenia and is classified as a Class 4 chemical drug.

This approval confirms that Brexpiprazole Tablets meet relevant drug registration requirements under the "Drug Administration Law of the People's Republic of China," enriching the company's product pipeline.

The mechanism of action for Brexpiprazole in treating schizophrenia is not fully understood, but it is believed to involve partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, combined with antagonist activity at serotonin 5-HT2A receptors. The company cautioned investors about potential uncertainties related to production and sales, influenced by national policies and market conditions.